AtriCure Inc

The global atrial fibrillation treatment devices market is projected to grow from USD 9.6 billion in 2026 to USD 29.0 billion by 2035, at a compound annual growth rate of 13.1%, according to a new report from ResearchAndMarkets.com. The market expansion is driven by the rising prevalence of atrial fibrillation, an aging population, and increasing adoption of advanced ablation and left atrial appendage closure technologies. Ablation catheters are expected to account for approximately 75% of market revenue, while the left atrial appendage closure segment is projected to grow at a CAGR of 13.4%, the fastest among device types. Pulsed field ablation is forecast to generate more than 60% of total market revenue by 2035. North America is projected to retain close to 50% of global revenue, while Asia-Pacific is expected to register the fastest regional growth. Key players include Abbott, AtriCure, Boston Scientific, Johnson & Johnson, and Medtronic.

AtriCure reported second-quarter fiscal 2026 results that beat consensus estimates, with revenue of $153.6 million and adjusted earnings per share of $0.18. Revenue exceeded expectations by $1.79 million and adjusted EPS surpassed forecasts by $0.16, an 800% beat. The company swung to a net income of $9 million from a net loss of $6.2 million a year earlier, while adjusted EBITDA reached $27 million. Gross margin expanded 270 basis points to 77.2%, driven by product innovation, geographic mix, and efficiencies. Management raised full-year revenue guidance to $602 million to $610 million and adjusted EBITDA guidance to $85 million to $89 million, with EPS expected between $0.05 and $0.13.

AtriCure shares surged 6.2% to close at $28.80 in the last trading session on heavy volume. The rally followed the company's presentation at the Goldman Sachs Global Healthcare Conference, where management reiterated its target of reaching $1 billion in revenue by 2030 and highlighted the market-expanding potential of its BoxX-NoAF and LeAAPS clinical trials. Investors also reacted to news of accelerated enrollment in the BoxX-NoAF trial, which could significantly broaden the company's addressable market if outcomes are positive. The stock currently carries a Zacks Rank of 3, or Hold.